VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival. by Aye M. Mon (5714912)

“…Data for cancer subtypes are shown in boxes numbered 1–11: 1: benign breast neoplasm (rank 6459, 1.4 fold-change, NS), 2: breast carcinoma (rank 833, 1.5 fold-change, p = 3.83x10^-5), 3: breast phyllodes tumor (rank 512, 1.2 fold-change, p = 0.002), 4: ductal breast carcinoma in situ (rank 1969, 1.5 fold-change, p = 0.002), 5: invasive breast carcinoma (rank 1060, 1.6 fold-change, p = 1.28x10^-5), 6: invasive ductal and invasive lobular breast carcinoma (rank 941, 1.5 fold-change, p = 6.76x10^-22), 7: invasive ductal breast carcinoma (rank 613, 1.5-fold change, p = 2.71x10^-71), 8: invasive lobular breast carcinoma (rank 947, 1.3 fold-change, p = 3.64x10^-28), 9: medullary breast carcinoma (rank 400, 1.8 fold-change, p = 3.25x10^-12), 10: mucinous breast carcinoma (rank 1932, 1.4 fold-change, p = 7.41x10^-10) and 11: tubular breast carcinoma (rank 1253, 1.4 fold-change, p = 1.24x10^-17). …”

Dox-inducible expression of HA-MAD1 in colon is sufficient to decrease p53 expression and cause chromosome missegregation. by Sarah E. Copeland (13951506)

“…Large circles show mean of cells from 5 fields of view from a single animal. (D) Immunoblot showing p53 protein expression is decreased in colon tissue from 5-month old HA-MAD1 mice after 1 week of 6 mg/kg dox feed as compared to control. …”

Genes showing 1.5 fold expression decrease in D381 relative to heterozygous <i>TOR1/tor1</i>. by Wanjun Qi (5571359)

Trending decrease in Slfn family RNA expression from the splenic tissue of VC-Slfn3KO mice. by Emilie E. Vomhof-DeKrey (6900677)

Prdm5 loss results in decreased Collagen I and Decorin levels and leads to reduced bone formation <i>in vivo</i>. by Giorgio Giacomo Galli (165327)

Pravastatin activates SREBP2 in NSPCs. by Ross A. Carson (5184512)

Cycloheximide (CHX) treatment decreases production of rRNA transcripts by POLR1 and POLR3. by Martin Selinger (3195987)

“…<p>(A) DAOY cells were treated with CHX (100 μg/ml) for either 6 or 14 hours; for metabolic RNA labelling, 5-EU was added 2 hours before the sample collection. …”

Klf5 and eIF5a suppress Ang II–induced expression of NOX1 in VSMCs. by Dong Ma (584680)

Subjects:

Meat consumption reduction in Italian regions: Health co-benefits and decreases in GHG emissions by Sara Farchi (19555)

Effects of SNPs on the Protein Stability, Increasing or Decreasing. by Mirza Jawad Ul Hasnain (8351388)

YFV vaccine elicits a specific IgG response in immunocompetent BALB/c mice. by Ana C. Vicente Santos (11649118)

Step-wise evolution of drug resistance via CNV and LOH. by Pétra Vande Zande (17628246)

Table_2_A novel anxiety-associated SNP identified in LYNX2 (LYPD1) is associated with decreased protein binding to nicotinic acetylcholine receptors.xlsx by Kristin R. Anderson (5478734)

<i>IXR1</i> deletion restored the decreased expression of <i>CLB1</i> caused by <i>PUF5</i> deletion. by Megumi Sato (4116994)

LOH at <i>KSR1</i> affects cellular lipid profiles, intracellular FLC concentrations, drug efflux, and sterol levels. by Pétra Vande Zande (17628246)

Nonsense allele results in mislocalization of Ksr1p. by Pétra Vande Zande (17628246)

SinV infection causes a decrease in Neuro 2a cells number and viability. by Leandro Silva da Costa (327641)

Comparing the product effect on changes in body weight of all groups before and after feeding, g. by Fatima Dikhanbayeva (11501962)

Subjects:

The results of assay of blood serum biochemical parameters after experiment. by Fatima Dikhanbayeva (11501962)

Subjects:

Gramine Derivatives Targeting Ca²⁺ Channels and Ser/Thr Phosphatases: A New Dual Strategy for the Treatment of Neurodegenerative Diseases by Rocío Lajarín-Cuesta (1530580)

“…Hence, we propose this multitarget approach as a new and promising strategy for the treatment of neurodegenerative diseases.…”